Metanova Labs, led by CEO Micaela Bazo, is transforming drug discovery using Bittensor’s decentralized AI network. The platform incentivizes global contributors through crypto rewards, enabling the screening of billions of molecules against protein targets.
Drug discovery traditionally costs $2.6 billion and takes a decade. Metanova’s decentralized virtual screening proof of concept launched in March, introducing dual incentives for miners to submit molecules or compete via algorithms. This approach expands potential molecules to 65 billion through combinatorial reactions.
The process involves derisking assets, generating intellectual property, and iterative testing to ensure safety and efficacy. Personalized medicine benefits from this scalable innovation, addressing individual treatment variability.